secwatch.observer — SEC 8-K summary
======================================

Issuer:     Septerna, Inc. (SEPN)
CIK:        0001984086
Form:       8-K
Filed at:   2025-01-06T23:59:59+00:00
Accession:  0001193125-25-001834
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Septerna appoints Gil Labrucherie as CFO effective Jan 6, 2025; interim CFO Ran Xiao resigns
--------------------------------------------------------------------------------

- Gil Labrucherie appointed CFO, principal financial and accounting officer, effective Jan 6, 2025.
- Labrucherie brings 25+ years biotech experience, most recently CFO of Acelyrin and Nektar Therapeutics.
- Compensation includes $485k base salary, 40% target bonus, and stock option for 222,000 shares.
- Interim CFO Ran Xiao resigns from CFO role but remains VP of Finance and Business Operations.
- Labrucherie has raised over $1.5B in equity and generated $1B+ in strategic partnering value.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1984086/000119312525001834/0001193125-25-001834-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1984086/000119312525001834/d753888d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-001834

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer